10 research outputs found
Combined therapy for oral cavity and oropharyngeal squamous cell carcinoma
Background. The aim of the study was to emphasize the importance of surgical management of squamous cell carcinoma (SCC) in the head and neck to find the most important predictive factor for cervical lymph node metastasis and prognostic factor for survival. The use of multimodality therapy is being discussed as well. Patients and methods. From June 1st, 1992 to May 31st, 1998, 154 patients with oral cavity and oropharyngeal SCC were admitted to the Department of Otorhinolaryngology and Cervicofacial Surgery in the Teaching Hospital of Maribor. The criteria for inclusion into the study were met by 142 patients, but only 62/142 patients entered the multimodality protocol (surgery and postoperative radiotherapy). These 62/142 patients were treated surgically and 49 of them were postoperatively irradiated, while 13/62 declined postoperative radiotherapy. Surgical specimen was evaluated for positive or negative lymph nodes, tumor margins and the depth of invasion. Tumor cells were stained for Ki67 proliferative factor. Results. The depth of invasion was the most important predictive factor for the neck metastases in multivariate model including also the grade, pT and T. pN was found to be important in determining the overall survival using Cox regression model (p>0,05). A statistically important discrepancy between N and pN classification was found. In 23 cases N was overrated and in 3 cases underrated. The overall 5-year disease specific survival was 55%. Ki67 correlated with the grade of tumor differentiation. No statistically significant correlation was found with lymph node metastases. Conclusions. The depth of invasion is the most important determining the occurrence of the neck metastases whereas the N status determines the survival
Priporočila za obravnavo bolnikov s pljučnim rakom
No abstract.Ni abstrakta
Potek zdravljenja bolnice s patološkim brisom in negativnim testom HPV
Presejalni program zgodnjega odkrivanja materničnega vratu temelji v Sloveniji na citološkem pregledu brisov materničnega vratu. V primeru patološkega citološkega izvida je potrebno opraviti tudi dodatne diagnostične preiskave in načrtovati ustrezno zdravljenje. Čeprav je velika večina predrakavih in rakavih bolezenskih sprememb na materničnem vratu pogojena s HPV-okužbo, pa se je potrebno zavedati, da obstoja možnost bolezni redko tudi pri populaciji z negativnim izvidom testa HPV
Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches
To overcome obstacles within the Slovenian organised cervical cancer screening programme, a randomised pilot study of human papillomavirus (HPV) self-sampling among non-attenders was performed, aiming to assess three different screening approaches
Priporočila za obravnavo bolnikov s pljučnim rakom
In 2019, the Recommendations for the management of patients with lung cancer were published bringing much-needed standardisation of diagnosis and treatment to improve survival of patients with lung cancer. Three years after the original Recommendations were published, the update of the Recommendations brings the most innovations in the chapter on systemic treatment of patients with lung cancer. This reflects the remarkable progress made in the field of understanding the oncogenesis and biology of lung cancer and thus the development of new drugs. The burden of lung cancer remains high, as lung cancer is still the most common cause of cancer related death in our country and worldwide. Lung cancer is responsible for one of five cancer-related deaths. Almost one third of patients with lung cancer do not receive any oncological treatment, either because of poor performance status, comorbidities or the extent of the disease. Half of the patients have metastatic disease at diagnosis, resulting in only small improvements in survival despite advances in the treatment of lung cancer patients. These data remind us that if we are to make major shifts in the management of lung cancer patients, we will need to take different approaches. The most promising seems to be the detection of early stages of lung cancer which offers the best treatment results. The Recommendations written here are guidelines for the management of patients with lung cancer. Only with comprehensive multidisciplinary treatment approach, the best outcome from the prognostically unfavourable disease can be offered.Leta 2019 so bila objavljena Priporočila za obravnavo bolnikov s pljučnim rakom, ki so v slovenski prostor vnesla prepotrebno poenotenje diagnostike in zdravljenja z namenom izboljšanja preživetja bolnikov s pljučnim rakom. Posodobitev Priporočil tri leta po izidu izvirnika prinaša največ novosti v poglavju o sistemskem zdravljenju bolnikov s pljučnim rakom. To kaže na izjemen napredek na področju razumevanja onkogeneze in biologije pljučnega raka ter s tem razvoja novih zdravil. Breme pljučnega raka ostaja veliko, saj je pljučni rak pri nas in v svetu še vedno najpogostejši vzrok smrti zaradi raka. Za vsako peto smrt zaradi raka je odgovoren pljučni rak. Skoraj tretjina bolnikov s pljučnim rakom ne prejme specifičnega onkološkega zdravljenja, bodisi zaradi slabega stanja zmogljivosti, spremljajočih bolezni ali obsega bolezni. Polovica bolnikov ima ob diagnozi razsejano bolezen, zaradi česar izboljšanje preživetja z malimi koraki sledi napredku v zdravljenju bolnikov s pljučnim rakom. Ti podatki nas opominjajo, da se bomo morali za velike premike v obravnavi bolnikov s pljučnim rakom lotiti drugačnih pristopov. Kot najbolj obetavno se ponuja zgodnje odkrivanje bolezni, ko so možnosti ozdravitve pljučnega raka najboljše. Zapisana Priporočila so usmeritev za obravnavo bolnikov s pljučnim rakom. Le s sodobnim multidisciplinarnim pristopom obravnave lahko bolniku ponudimo zdravljenje, ki mu omogoča najboljši izhod prognostično neugodne bolezni
Recommendations for diagnosis and treatment of patients with lung cancer
In 2019, the Recommendations for the management of patients with lung cancer were published bringing much-needed standardisation of diagnosis and treatment to improve survival of patients with lung cancer. Three years after the original Recommendations were published, the update of the Recommendations brings the most innovations in the chapter on systemic treatment of patients with lung cancer. This reflects the remarkable progress made in the field of understanding the oncogenesis and biology of lung cancer and thus the development of new drugs. The burden of lung cancer remains high, as lung cancer is still the most common cause of cancer related death in our country and worldwide. Lung cancer is responsible for one of five cancer-related deaths. Almost one third of patients with lung cancer do not receive any oncological treatment, either because of poor performance status, comorbidities or the extent of the disease. Half of the patients have metastatic disease at diagnosis, resulting in only small improvements in survival despite advances in the treatment of lung cancer patients. These data remind us that if we are to make major shifts in the management of lung cancer patients, we will need to take different approaches. The most promising seems to be the detection of early stages of lung cancer which offers the best treatment results. The Recommendations written here are guidelines for the management of patients with lung cancer. Only with comprehensive multidisciplinary treatment approach, the best outcome from the prognostically unfavourable disease can be offered